b'DATA COURTESY OF DRUGSDRUGS BY PHASEINVESTIGATIONAL APPROVEDPRECLINICAL53.1%DISCOVERY19.7% PHASE I PHASE II MARKETED8.9% 9.4% 6.9%PHASE III1.9%DRUGS BY SPECIALTYALL PHASES OF DEVELOPMENTONCOLOGY29.7%OTHER DRUGS23.9%INFECTIOUS DISEASE17.2% CENTRAL NERVOUS SYSTEM13.1%IMMUNOLOGY6.9% CARDIOVASCULAR METABOLIC 4.7% DISORDERS4.4%2023-2024 BIOSCIENCE COLORADO 47'